

# Psychological Medicine

## The non-specific nature of mental health and structural brain outcomes following childhood trauma --Manuscript Draft--

Manuscript Number:	PSM-D-20-02245R2
Full Title:	The non-specific nature of mental health and structural brain outcomes following childhood trauma
Article Type:	Original Article
Corresponding Author:	Theresa Katharina Haidl Faculty of Medicine and University Hospital of Cologne, University of Cologne Cologne, GERMANY
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Faculty of Medicine and University Hospital of Cologne, University of Cologne
Corresponding Author's Secondary Institution:	
First Author:	Theresa Katharina Haidl
First Author Secondary Information:	
Order of Authors:	Theresa Katharina Haidl
	Dennis Hedderich
	Marlene Rosen
	Nathalie Kaiser
	Mauro Seves
	Thorsten Lichtenstein
	Penzel Nora
	Julian Wenzel
	Lana Kambeitz-Illankovic
	Anne Ruef
	David Popovic
	Frauke Schultze-Lutter
	Katie Chisholm
	Rachel Upthegrove
	Raimo Salokangas
	Christos Pantelis
	Eva Meisenzahl
	Stephen Wood
	Paolo Brambilla
	Stefan Borgwardt
	Stephan Ruhrmann
	Joseph Kambeitz
	Nikolaos Koutsouleris

Order of Authors Secondary Information:	Martin
	K.R.
	J.
Manuscript Region of Origin:	GERMANY
Abstract:	<p>Background: Childhood trauma (CT) is associated with an increased risk of mental health disorders, however it is unknown whether this represents a diagnosis-specific risk factor for specific psychopathology mediated by structural brain changes. Our aim was to explore whether (i) a predictive CT pattern for transdiagnostic psychopathology exists, and whether (ii) CT can differentiate between distinct diagnosis-dependent psychopathology. Furthermore, we aimed to identify association between CT, psychopathology and brain structure.</p> <p>Methods: We used multivariate pattern analysis in data from 643 participants of the Personalised Prognostic Tools for Early Psychosis Management study (PRONIA), including healthy controls (HC), recent onset psychosis (ROP), recent onset depression (ROD) and individuals clinically at high-risk for psychosis (CHR). Participants completed structured interviews and self-report measures including the Childhood Trauma Questionnaire, SCID diagnostic interview, BDI, PANSS, Schizophrenia Proneness Instrument, Structured Interview for Prodromal Symptoms and structural MRI, analysed by voxel-based morphometry.</p> <p>Results: (i) Patients and HC could be distinguished by their CT pattern with a reasonable precision (balanced accuracy of 71.2% (sensitivity=72.1%, specificity=70.4%, <math>p &lt; .001</math>) (ii) Subdomains 'emotional neglect' and 'emotional abuse' were most predictive for CHR and ROP, while in ROD 'physical abuse' and 'sexual abuse' were most important. The CT pattern was significantly associated with the severity of depressive symptoms in both ROD and CHR. No associations between group-separating CT patterns and brain structure were found.</p> <p>Conclusions: These results indicate that CT poses a transdiagnostic risk factor for mental health disorders, possibly related to depressive symptoms. While differences in the quality of CT exposure exist, diagnostic differentiation was not possible suggesting a multi-factorial pathogenesis.</p>

Haidl & Hedderich et al., 2020

## The non-specific nature of mental health and structural brain outcomes following childhood trauma

Theresa K. Haidl, MD<sup>1\*</sup>; Dennis M. Hedderich, MD<sup>2,3\*</sup>; Marlene Rosen, MSc<sup>1</sup>; Nathalie Kaiser, MSc<sup>1</sup>; Mauro Seves, MSc<sup>1</sup>; Thorsten Lichtenstein, MD<sup>2</sup>; Nora Penzel, MSc<sup>1</sup>; Julian Wenzel, MSc<sup>1</sup>; Lana Kambeitz-Illankovic, PhD<sup>1</sup>; Anne Ruef, PhD<sup>4</sup>; David Popovic, MD<sup>4,5</sup>; Frauke Schultze-Lutter, PhD<sup>6,7,8</sup>; Katharine Chisholm, PhD<sup>9,10</sup>; Rachel Upthegrove, MBBS FRCPsych<sup>9</sup>, PhD; Raimo K. R. Salokangas, MD, PhD, MSc, PsD<sup>11</sup>; Christos Pantelis, MBBS MD FRANZCP FRCPsych<sup>12</sup>; Eva Meisenzahl, MD<sup>6</sup>; Stephen J. Wood, PhD<sup>9,13,14</sup>; Paolo Brambilla, MD<sup>15,16</sup>; Stefan Borgwardt, MD<sup>17,18</sup>; Stephan Ruhrmann, MD<sup>1</sup>; Joseph Kambeitz, MD<sup>1\*\*</sup> and Nikolaos Koutsouleris, MD<sup>4\*\*</sup>

1) Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany

2) Department Diagnostic and Interventional Radiology, University of Cologne, Cologne, Germany

3) Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, School of Medicine Technical University of Munich, Munich, Germany

4) Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Germany

5) International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Munich, Germany

6) Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany

7) Department of Psychology and Mental Health, Faculty of Psychology, Airlangga University, Surabaya, Indonesia

8) University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland

9) Institute of Mental Health, University of Birmingham, United Kingdom

10) Department of Psychology, Aston University, United Kingdom

11) Department of Psychiatry, University of Turku, Finland

12) Melbourne Neuropsychiatry Centre, University of Melbourne & Melbourne Health, Victoria, Australia

13) Orygen, the National Centre of Excellence for Youth Mental Health, Melbourne, Australia

14) Centre for Youth Mental Health, University of Melbourne, Australia

15) Department of Neurosciences and Mental Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

16) Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

17) Department of Psychiatry (Psychiatric University Hospital, UPK), University of Basel, Switzerland

18) Department of Psychiatry and Psychotherapy, University of Lübeck, Germany

# See PRONIA consortium author list

\*shared first authorship

\*\* shared senior authorship

Corresponding Author and Address for Reprint Requests:

Theresa Haidl, MD

Department of Psychiatry and Psychotherapy,

University of Cologne,

Kerpener Straße 62,

50937 Cologne, Germany

Phone: +49 (0)221 – 478 4005

Fax: +49 (0)221 – 478 7490

E-Mail: [theresa.haidl@uk-koeln.de](mailto:theresa.haidl@uk-koeln.de)

### Financial support

PRONIA is a Collaborative Project funded by the European Union under the 7th Framework Programme under grant agreement n° 602152. R.U. reports grants from Medical Research Council, grants from the National Institute for Health Research, and personal fees from Sunovion, outside the submitted work. N.K. and R.S. received honoraria for talks presented at education meetings organized by Otsuka/Lundbeck. C.P. participated in advisory boards for Janssen-Cilag, AstraZeneca, Lundbeck, and Servier and received honoraria for talks presented at educational meetings organized by AstraZeneca, Janssen-Cilag, Eli Lilly, Pfizer, Lundbeck, and Shire. C.P. acknowledges support by an Australian National Health & Medical Research Council (NHMRC) Senior Principal Research Fellowship (ID: 1105825), a NHMRC Program Grant (ID: 1150083). JK reports funding by the DFG (KA 4413/1-1) and received honoraria for talks presented at educational meetings organized by Janssen and Otsuka/Lundbeck. All other authors report no biomedical financial interests or potential conflicts of interest. The funding organizations stated above were not involved in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Word count** (text only, excluding abstract, references, tables/figures, appendices/supplementary material): 3757

## **Abstract**

**Background:** Childhood trauma (CT) is associated with an increased risk of mental health disorders, however it is unknown whether this represents a diagnosis-specific risk factor for specific psychopathology mediated by structural brain changes. Our aim was to explore whether (i) a predictive CT pattern for transdiagnostic psychopathology exists, and whether (ii) CT can differentiate between distinct diagnosis-dependent psychopathology. Furthermore, we aimed to identify association between CT, psychopathology and brain structure.

**Methods:** We used multivariate pattern analysis in data from 643 participants of the Personalised Prognostic Tools for Early Psychosis Management study (PRONIA), including healthy controls (HC), recent onset psychosis (ROP), recent onset depression (ROD) and patients clinically at high-risk for psychosis (CHR). Participants completed structured interviews and self-report measures including the Childhood Trauma Questionnaire, SCID diagnostic interview, BDI-II, PANSS, Schizophrenia Proneness Instrument, Structured Interview for Prodromal Symptoms and structural MRI, analysed by voxel-based morphometry.

**Results:** (i) Patients and HC could be distinguished by their CT pattern with a reasonable precision (balanced accuracy of 71.2% (sensitivity=72.1%, specificity=70.4%,  $p<.001$ ) (ii) Subdomains 'emotional neglect' and 'emotional abuse' were most predictive for CHR and ROP, while in ROD 'physical abuse' and 'sexual abuse' were most important. The CT pattern was significantly associated with the severity of depressive symptoms in ROD, ROP and CHR, as well as with the PANSS total and negative domain scores in the CHR patients. No associations between group-separating CT patterns and brain structure were found.

**Conclusions:** These results indicate that CT poses a transdiagnostic risk factor for mental health disorders, possibly related to depressive symptoms. While differences in the quality of CT exposure exist, diagnostic differentiation was not possible suggesting a multi-factorial pathogenesis.

## Introduction

Childhood trauma (CT) is a frequent form of maltreatment comprising sexual, physical, and emotional dimensions. In Western countries 30% to 40% of the adult population reported experiences with at least some form of maltreatment during childhood (Scher, Forde, McQuaid, & Stein, 2004). CT was revealed to influence the further course of life of the affected individuals, frequently leading to psychological symptoms and impairment in adulthood (Kessler et al., 2010; Scott, McLaughlin, Smith, & Ellis, 2012). It has been shown to be associated with an increased risk for psychiatric disorders such as major depression, anxiety disorders, addiction, post-traumatic stress disorder (PTSD) and psychosis, including patients at clinical high-risk for psychosis (CHR) (Kessler et al., 2010; Palmier-Claus, Berry, Bucci, Mansell, & Varese, 2016; Sahin et al., 2013; Scott et al., 2012; Varese et al., 2012). Even in the general population, CT seems to have long-standing effects on individuals' social perception (Salokangas, From, Luutonen, & Hietala, 2018). Due to its high prevalence and detrimental effects to both, mental health and associated socioeconomic costs (Fang, Brown, Florence, & Mercy, 2012), a better understanding of CT as a risk factor is essential. Furthermore, the fact that CT occurs during a period of important neurodevelopmental steps underlines the potential for prevention or better care for CT victims to contribute to lower lifetime burden of psychiatric diseases (Mikton & Butchart, 2009).

The sum of trauma exposure during childhood has been established as an important risk factor for mental health disorders. However, this has not been investigated in detail, although CT covers five different subcategories of different trauma exposure. These are in detail physical abuse (PA), physical neglect (PN), emotional abuse (EA), emotional neglect (EN) and sexual abuse (SA) (Bernstein & Fink, 1998). A promising approach to investigate the complex granularity of CT as a risk factor is multivariate pattern analysis (MVPA) which was previously shown to identify neuropsychiatric conditions based on e.g. neuroimaging data (Kambeitz et al., 2015). The initial publication from the PRONIA study was on the prediction of functional and treatment outcomes based on clinical baseline data across multiple sites (Koutsouleris et al., 2018). Furthermore, two publications from the PRONIA consortium focused on different aspects of CT: Popovic et al. (2020) identified distinct volumetric brain patterns associated

with single dimensions of CT (in particular physical and sexual abuse and emotional trauma) in a transdiagnostic approach. Salokangas et al. (2021) focused on CT in smaller patient groups and specifically investigated differences with respect to frontal lobe and hippocampal-amygdala complex volumes. In contrast, our study focuses on the potential ability of separating healthy controls and patient groups using machine learning techniques, and to identify potential clinical and volumetric brain correlates of CT in the entire cohort.

To answer these questions the present study first investigated the discriminative value of CT for the individualized identification of transdiagnostic and diagnosis-specific psychiatric disorders using MVPA. In a second step we examined whether found CT patterns correlate with measures of psychopathology and/ or altered brain structure. The investigation was carried out in the PRONIA database ('Personalized Prognostic Tools for Early Psychosis Management'; [www.pronia.eu](http://www.pronia.eu)), a large, multi-site European cohort consisting of patients with recent onset depression (ROD), recent onset psychosis (ROP), individuals clinically at high-risk for psychosis (CHR) and healthy controls (HC).

#### Aims of the study

We aimed to investigate whether (i) a predictive pattern of childhood trauma for transdiagnostic psychopathology exists, and whether (ii) childhood trauma can differentiate between distinct diagnosis-dependent psychopathology. Moreover, our aim was to identify associations between childhood trauma, psychopathology and brain structure.

## **Methods**

### *Participants*

For the quality assurance of our proceedings, we followed the “Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis” (TRIPOD) checklist for prediction model development and validation (Collins, Reitsma, Altman, & Moons, 2015).

All participants were recruited within the PRONIA project (‘Personalized Prognostic Tools for Early Psychosis Management’). PRONIA is a multisite observational study funded by the European Union under the 7th Framework Programme (grant agreement n° 602152). Seven clinical centers in five European countries participated in the evaluation of patients with recent onset depression (ROD), recent onset psychosis (ROP), patients clinically at high-risk for psychosis (CHR) and healthy controls (HC). Within a longitudinal study design a comprehensive battery of clinical assessment tools were used every three months over 18 months (**see supplemental Figure 1**). Neuroimaging examinations were carried out at the baseline and the 9-month follow-up points. The entire study design has been previously described detailed in Koutsouleris et al. (2018).

All adult participants provided their written informed consent prior to study inclusion. Minors provided written informed assent and guardians written informed consent. The study was registered at the German Clinical Trials Register (DRKS00005042). The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human subjects/ patients were approved by the local research ethics committees.

### *Inclusion and exclusion criteria*

The included persons were aged between 15 and 40 years and recruited into the study between 1<sup>st</sup> of February 2014 and 1<sup>st</sup> of May 2016. Patients with CHR were included by Cognitive Disturbances

(COGDIS) criteria, assessed by the Schizophrenia Proneness Instrument (SPI-A) (Schultze-Lutter, Addington, Ruhrmann, & Klosterkötter, 2007), and/ or UHR criteria (Phillips, Yung, & McGorry, 2000), assessed using a modified version of the Structured Interview for Prodromal Syndromes (SIPS) (McGlashan, Walsh, & Woods, 2010). For ROD, specific inclusion criteria were having a DSM-IV (American Psychiatric Association, 2000) Major Depressive Episode that was present within the past three months and did not last longer than 24 months. ROP fulfilled DSM-IV criteria for affective or non-affective psychosis within the last 24 months and not before. General inclusion and exclusion criteria have been described in detail in Koutsouleris et al. (2018) and were detailed depicted in **supplemental Table S1**.

#### *Procedure and instruments*

The data used in this study were all acquired at baseline. As mentioned above, psychopathology of CHR patients was assessed using SIPS and SPI-A. ROP and ROD were diagnosed by DSM-IV. Depressive syndrome severity was additionally measured using the Beck-Depression-Inventory II (BDI-II) (Hautzinger, Bailer, Worall, & Keller, 1995). Positive and negative symptoms were assessed by the Positive and Negative Syndrome Scale (PANSS) (Kay, Fiszbein, & Opler, 1987). For the assessment of CT, the Childhood Trauma Questionnaire (CTQ), developed by Bernstein and Fink (1998), was used. The CTQ is a self-assessment tool for the retrospective recording of mistreatment and neglect in childhood. It consists of 28 items, whereby three items (10, 16, 22) are used to determine denial and trivialization. It includes five subscales; emotional abuse (EA), physical abuse (PA), sexual abuse (SA), emotional neglect (EN) and physical neglect (PN). Rating was carried out on a 5-point Likert scale (0= never to 4= very often). The convergent and discriminative validity has been reported as being good (Bernstein & Fink, 1998). In addition, the cumulative sum of the equivalent doses received until T0 was calculated for SSRIs (Hayasaka et al., 2015), chlorpromazine (Leucht, Samara, Heres, & Davis, 2016) olanzapine (Leucht et al., 2016) and benzodiazepines (diazepam) (Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group, 2017).



*MRI acquisition, preprocessing and analysis*

Participants underwent a comprehensive imaging protocol at seven sites respecting a minimal harmonization protocol including high resolution 3D T1-weighted imaging. Detailed scanner and sequence specifications for all sites can be found in the **supplemental Table S2**. All images underwent quality control and were preprocessed using the CAT12 toolbox (version r1155; <http://dbm.neuro.uni-jena.de/cat12/>), an extension of SPM 12 as described previously (Koutsouleris et al., 2018). Images were smoothed with 10 mm before entering the subsequent analysis steps. The Quality Assurance framework of CAT12 was used to empirically check the quality of the GMV maps.

By computing the correlation of each image to all other 592 images, we found 11 (1.9%) images whose correlation exceeded two standard deviations from the sample mean. These images were inspected and 9 were removed because of MRI artifacts. Thus, 583 persons could be included in the VBM analysis (109 CHR patients, 115 ROD patients, 110 ROP patients and 249 HC). Notably, 98.47% of the images achieved a good overall weighted quality (B), and 83.0% of the data quality was rated with a B+ as provided by the internal quality assessment of CAT12 (Gaser & Dahnke, 2016). For analysis of brain structure and associations with CT, voxel-based morphometry (VBM) was employed. Preprocessed data entered a full-factorial general linear model design as implemented in SPM. Sex, site (coded as dummy regressors), and age were used as covariates of no interest to correct for potential confounds for VBM analyses. In order to investigate possible sex differences, male and female participants were also analyzed separately. Global proportional scaling for total intracranial volume (TIV) was used to adjust for different global brain volume differences. Contrasts were defined for main-effects and interaction analyses to assess differences in mean and slope effects of associations between CTQ-based decision scores (DS) and local GM. Threshold-free cluster enhancement (TFCE) was used as implemented in the TFCE toolbox for SPM with 5000 permutations (Smith & Nichols, 2009). Significance threshold was set at  $p < 0.05$ , Family-wise error (FWE) corrected.

### *Machine learning strategies*

To investigate discriminative patterns of CT experience in HC vs. the combined three patient groups (PAT), we used a L2-regularized logistic regression as provided by the LIBLINEAR library (Fan, Chang, Hsieh, & Lin, 2008), which offers methods for classifying individuals instead of describing statistical group differences.

We used our open-source machine learning toolkit NeuroMiner (<https://github.com/neurominer-git/>) to implement a fully automated machine learning pipeline. We trained different models to predict psychiatric disorders based on the single CTQ items;

1. **PAT vs. HC**
2. **HC vs. CHR; HC vs. ROD; HC vs. ROP**
3. **ROD vs. CHR; ROD vs. ROP; CHR vs. ROP**

We followed the internal-external validation approach recommended for the assessment of model generalizability in multi-site studies (Steyerberg & Harrell, 2016) and validated our models using nested leave-one-site-out cross-validation (LOSOCV) (see in detail **supplemental Methods**).

To compare the multivariate versus univariate methods, we repeated the HC vs. PAT analysis after replacing the  $L_2$ -regularized logistic regression (L2-LR) (Fan et al., 2008) algorithm with a univariate logistic regression model (uLR) in NeuroMiner. Algorithm performance was measured using the balanced accuracy (BAC) of the out-of-training (OOT) group membership predictions and assessed for significance using 1000 random label permutations (Golland & Fischl, 2003). Predictive features for each L2-LR model were compared by their mean weights.

A further validation analysis assessed whether our model generalized across study groups. Therefore, we used LOSOCV to train and cross-validate three binary L2-LR-based diagnostic classifiers (HC vs. CHR; HC vs. ROD; HC vs. ROP) using the identical algorithmic setup described above. Each trained classification ensemble was then applied to the CTQ data of the other two clinical study groups

following an out-of-sample cross-validation (OOCV) approach. Class membership probabilities/ DS of the patients in the held-back study groups were computed as for the OOT predictions.

These main analyses were supplemented by an investigation of univariate associations between measures of *current* psychopathology and the OOT DS of clinical participants produced by the L2-LR algorithms, which were trained in the HC vs CHR, HC vs. ROD and HC vs ROP comparisons. For the ROD, ROP and CHR groups, the correlations of the CTQ-based DS with the BDI-II, SIPS-P, SIPS-N, SIPS-D, SIPS-G, PANSS total, positive, negative and general domain scores were examined respectively. Furthermore, the relationship between the equivalent doses of the individual drug classes (neuroleptics, SSRIs, benzodiazepines) and the CTQ-based DS was calculated for each group. In order to exclude recall bias in older participants (with longer time spans between CT and study inclusion), we performed correlation analyses between CTQ-based DS and age at study inclusion as a control analysis.

## Results

### *Study group characteristics*

643 subjects (57.2% male, mean age  $27.69 \pm 5.99$  years) were included in the analysis. These consisted of  $n=262$  (40.7%) HC,  $n=122$  (19.0%) CHR,  $n=130$  (20.2%) ROD and  $n=129$  (20.1%) ROP. CTQ total scores and subdomain scores were significantly different between PAT and HC. No group differences were found between the PAT groups ROP, ROD and CHR regarding the total CTQ score. Please see **Table 1** and **supplemental Table S3** for details. The **supplementary Table S4** shows the mean values of the drug equivalent doses that have been taken cumulatively so far. As expected, the highest equivalent doses for antipsychotics were found in ROP patients (chlorpromazine=8072.71 mg/d, olanzapine=280.02 mg/d), followed by CHR patients (chlorpromazine= 1025.06 mg/d, olanzapine= 42.04 mg/d). Surprisingly, the highest equivalent doses for SSRIs were found in CHR patients (3864.95 mg/d), followed by ROD patients (2630.83). We did not find an association between patient age and DS, making an age-dependent recall bias unlikely to have influenced our results (see **supplementary Table S5**).

### *Childhood trauma profiles predict general psychopathology.*

The classifier distinguishing HC from PAT performed with a BAC of 71.2% (sensitivity: 72.1%, specificity: 70.4%). Leave-site-out validation yielded good generalizability of the CTQ-based discriminative model (see **Table 2**). In order to deduct a CT profile predictive of general psychopathology, weights of CTQ single items from the MVPA were recorded and are depicted in **Figure 1**. It must be emphasized that the resulting values do not allow to conclude on the direction of the prediction. The highest weights related to items within the subdomains EN and EA, namely: **CTQ Item 5**; ‘There was someone in my family who helped me feel that I was important or special’, **CTQ Item 14**; ‘People in my family said hurtful or insulting things to me’, and **CTQ Item 13**; ‘People in my family looked out for each other.’ The uLR analyses for the same classification (HC vs. PAT) led to a BAC of 67.1% (sensitivity: 66.0%, specificity: 68.2%). For detailed results, please see **Table 2**.

### *Childhood trauma profiles for diagnosis-specific psychopathology*

Classifying the three diagnostic groups within the PAT cohort, namely CHR, ROD, and ROP did not perform above chance level (CHR vs ROD: BAC= 46.1%, sensitivity=35.8%, specificity= 56.3%; CHR vs ROP: BAC= 47.1%, sensitivity= 42.5%, specificity= 51.7%; ROD vs ROP: BAC= 51.9 sensitivity= 58.0%, specificity= 45.3%). However, classifiers separating between HC and individual PAT groups performed well (HC vs ROD: BAC= 67.2%, sensitivity= 75.6%, specificity= 58.9%; HC vs CHR: BAC= 72.1%, sensitivity= 72.4%, specificity= 71.8%; HC vs ROP: BAC= 70.8%, sensitivity= 74.4%, specificity= 67.2%; please see **Table 2**).

Regarding the differentiation of HC vs CHR, highest weights belonged to items of the subdomain EA and EN (see **Figure 1**); **CTQ Item 14**; 'People in my family said hurtful or insulting things to me', **CTQ Item 13**; 'People in my family looked out for each other', and **CTQ Item 28**; 'My family was a source of strength and support.'

Analysing the profile of HC vs ROD revealed the highest weights in items of the subdomains PA, SA and EA (see **Figure 1**); **CTQ Item 17**; 'I got hit or beaten so badly that it was noticed by someone like a teacher, neighbour, or doctor', **CTQ Item 24**; 'Someone molested me', and **CTQ Item 14**; 'People in my family said hurtful or insulting things to me.'

Describing the profile, which is distinguishing HC vs ROP items of the subdomains EA, EN and PN were most predictive (see **Figure 1**); **CTQ Item 25**; 'I believe that I was emotionally abused', **CTQ Item 13**; 'People in my family looked out for each other', and **CTQ Item 2**; 'I knew that there was someone to take care of me and protect me.'

### *Correlation between childhood trauma and psychopathology*

Across all groups, correlations between the CTQ-based DS and GAF symptoms ( $r = .388$ ,  $p < 0.01$ ) as well as disability and impairment ( $r = .412$ ,  $p < 0.01$ ) were moderate to strong. In the CHR group, there were no associations between the CTQ-based DS and any SIPS domain, but a weak correlation between

the DS and the BDI total score was observed ( $r = -.175$ ,  $p = 0.028$ ). Moreover, a weak correlation between the PANSS total and ( $r = -.191$ ,  $p = 0.038$ ) and the PANSS negative domain score ( $r = -.196$ ,  $p = 0.033$ ) was seen in the CHR patients. Regarding the ROD group, a moderate association between the CTQ-based DS and the BDI total score was found ( $r = -0.278$ ,  $p = .001$ ). In the ROP group, there was no significant correlation between the PANSS scores and the CTQ-based DS but a moderate association between the BDI total score and the CTQ-based DS ( $r = -.246$ ,  $p = 0.003$ ). For details see please **Table 3**.

#### *Correlation between childhood trauma and medication*

Across all groups, weak negative correlations were found between the CTQ-based DS and all types of medication (chlorpromazine  $r = -.213$ ,  $p = <0.001$ , olanzapine  $r = -.213$ ,  $p = <0.001$ , SSRI  $r = -.193$ ,  $p = <0.001$ , benzodiazepine (diazepam)  $r = -.128$ ,  $p = 0.001$ ). Interestingly, however, no significant correlations were found in the individual groups, except for a weak positive correlation with benzodiazepine in HC individuals. For details, please see **supplemental Table S6**.

#### *Correlation between childhood trauma and brain structure*

Despite several methodological approaches and adjusted statistical thresholds, we did not find any associations between CTQ-based DS and brain morphology in our cohort. Additionally, there were no significant associations between DS and brain morphology when examining male and female participants separately, also suggesting also no sex-specific brain alterations associated with CTQ-based DS.

## Discussion

We investigated CT and psychopathology in a large cohort of HC and patients with ROD, ROP and CHR using MVPA. We found that CT significantly predicted transdiagnostic psychopathology using MVPA, while separation of diagnosis-specific psychopathology was not achieved. Qualitative analysis of CT patterns emphasized the importance of EN and EA for ROP and CHR identification while PA and SA yielded importance in ROD patients. The CTQ-based DS was significantly associated with the current severity of depressive symptoms in the ROD, ROP and CHR group. Moreover, a correlation between the CTQ-based DS and the PANSS total and negative domain score was achieved in the CHR patients. However, no further associations with psychopathology or structural brain alterations were found. Weak correlations between CTQ-based DS and medication were discovered across all groups, while no correlations were observed in the single groups, except for a weak positive correlation with benzodiazepine in HC individuals. The latter might reflect negative consequences of CT at a subthreshold level, resulting in higher tension and anxiety treated with benzodiazepine.

In order to investigate the association between CT and psychopathology, we tested whether PAT and HC could be separated based on CTQ information using a machine-learning model. We found that this distinction could be made with acceptable accuracy on the individual level and that highest weights were assigned to domains pertaining to EA and EN. CT has been associated with several specific psychiatric diseases such as psychosis (Varese et al., 2012), unipolar depression (Rubino, Nanni, Pozzi, & Siracusano, 2009) and bipolar disorder (Palmier-Claus et al., 2016) and has been posited as a general risk factor for their development. Recent reviews and meta-analyses have shown that each subdomain of the CTQ is by itself significantly associated with the occurrence of psychiatric illness (Lindert et al., 2014; Nelson, Klumpp, Doebler, & Ehring, 2017; Varese et al., 2012). These results agree with our findings showing that CT is globally associated with early-stage psychiatric disease phenotypes but predictive of these illnesses from an individualized transdiagnostic perspective.

In order to test whether CTQ profiles also allow for diagnosis-specific prediction of early mental health disorders, we applied the same machine-learning model to separate CHR, ROP, and ROD. In these analyses, we found that it was not possible to distinguish reliably between the three diagnostic groups based on trauma exposure patterns. This is in line with studies describing increased rates of CT in psychiatric patients, irrespective of the exact diagnosis (Kessler et al., 2010; Palmier-Claus et al., 2016; Sahin et al., 2013; Scott et al., 2012; Varese et al., 2012). However, other studies exist describing distinct forms of early adversity in specific patient groups. Particularly, Bruni and colleagues found escape from home, cannabis abuse, psychological abuse, physical abuse and loneliness to be more frequent in patients with schizophrenic spectrum disorder than in patients with major depression or bipolar disorder (Bruni et al., 2018). Contrary to these results, our findings suggest that CT exposure is not associated with specific disorders but instead poses a rather general and transdiagnostic risk factor for early psychiatric disorders, which is also in line with an earlier study of our group (Popovic et al., 2020).

Regarding the individual CT patterns, we performed a qualitative comparison of the three CTQ questions which were assigned the highest weights. We identified the subdomains EN and EA playing the most important role across all groups. On the single item level, especially items that reflect the family climate showed the highest predictive power. These results are in line with a recent structure equation model analysis of Salokangas et al. (2019), which indicated that subdomains EN and PA had the strongest association with depression and psychosis. Furthermore, in our analysis EN and EA were most predictive in CHR patients, while PN was additionally predictive in psychosis. In contrast, an earlier work by Trauelsen et al. (2015) showed beside EA and EN, PA to be significantly associated with psychotic disorders. Other works revealed specific associations between SA and psychosis (Bentall, Wickham, Shevlin, & Varese, 2012) and hallucinations (Upthegrove et al., 2015). Interestingly, in ROD patients, besides EA, SA and PA were particularly predictive for a later depressive illness. In line with these observations, a meta-analysis of Lindert et al. (2014) pointed out that especially SA and PA are strongly associated with later depression and anxiety disorders. Although this meta-analysis identified



SA and PA as most important risk factors of depression and anxiety disorder, which are also common in CHR patients (Albert, Tomassi, Maina, & Tosato, 2018), we found EN and EA to play the most important role across all groups. One reason for this discrepancy might be the lower frequency of SA and PA compared to other CT domains in our sample that might have led to a underestimation of their role in our cohort. Thus, our results provide more comprehensive evidence for a differentiated neurobiological imprint of the CT in different psychiatric diseases, while at the same time highlighting emotional trauma as particularly relevant to a person's clinical phenotype.

Furthermore, we found evidence that the participants' CTQ-based DS was significantly associated with the current severity of depressive symptoms but not with psychotic symptoms (positive, negative and general) in the ROD, ROP and CHR groups. Moreover, pre-psychotic symptoms measured by the SIPS were not correlated with the DS in the CHR group but a weak relationship was detected between the CTQ-based DS and the PANSS total and negative domain scores. These results support the hypothesis that CT constitutes a dimension of vulnerability that is dependent of the current depressive state of the patients. This observation is in keeping with previous work of our group showing that an emotional trauma signature was significantly correlated with higher depression scores, lower levels of functioning, decreased quality of life and maladaptive personality traits (Popovic et al., 2020). In the past depressiveness has also been shown to be a mediating factor in the effect of CT on alcohol consumption (Salokangas, From, Luutonen, Salokangas, & Hietala, 2018) and suicidal thoughts (Salokangas et al., 2019).

No associations were found between the CTQ-based DS and brain structure. It can be assumed that the changes at the single item level of the CTQ are too subtle for individual prediction of disease. In a recent publication from our group, we performed a data-driven analysis of brain structure and phenotypic data including CT exposure and found three latent signatures specifically associated with CT. In this previous paper, and latent representations of brain-phenotype associations, SA was associated with aberrant volumes in the prefrontal cortex, the hippocampus and occipital lobe. EA and EN were associated with volumetric alterations in the occipital lobe and postcentral regions associated

with sensory processing. No associations between specific diagnostic groups and CT exposure were found, which is in line with the absence of diagnosis-specific associations between CT and early mental health diseases, and in keeping with current analysis (Popovic et al., 2020). In another previous mediation analysis of our group, PA was shown to be associated in particular with reduced volumes of the grey and white matter of the frontal lobe and amygdala-hippocampal complex in ROD and CHR patients (Salokangas et al., 2021). In addition, it was shown that the effect of PA on social anxiety in CHR patients was mediated by a reduced volume of gray matter in the frontal lobe. Since this was methodological a mediation analysis and not a machine learning approach, these results should not be regarded as contradictory.

### *Limitations*

Limitations of our study include the observational, retrospective and cross-sectional character of the study. As with most CT assessments, the CTQ assesses trauma retrospectively, thus, running the risk of a “recall bias” depending on the individual’s current mental health situation, including the influence of depression severity (Colman et al., 2016). Another possible limitation is the non-assessment of factors as the age at onset, the frequency and the extent of the suffering associated with exposure to CT. It must be critically taken into account that despite diverse adverse experiences, many victims of CT show no or only minor long-term psychological impairment, suggesting that resilience factors appear to be important mediating variables as well (Lee, Yu, & Kim, 2020). Therefore, in the future, suitable methods and longitudinal population data utilizing methods such as structure equation models, could be used to investigate the exact relationship between CT and functional or school outcome, against the background of the above-mentioned mediating variables.

### *Conclusions*

In summary, our work has demonstrated that CT constitutes a discriminative transdiagnostic fingerprint of at-risk mental states and early-stage mental disorders. Focusing on the most predictive items of our analyses, we were able to show that a violence-free, supportive family environment as

well as protection are important aspects for good mental health in later life. Our findings support the conclusions of a paper by Hudziak (2009) who called for a routine evaluation of CT history in persons presenting to mental health services in order to identify those who may need more intensive support and additional treatment. In line with that, Marshall and colleagues (Marshall, Shannon, Meenagh, Mc Corry, & Mulholland, 2018) emphasized the importance of special preventive measures, such as therapeutic intervention aimed at sufferers of past abuse, neglect and poor parenting to prevent 'trans-generational patterns' continuing with their own children. In the future, further analyses of the longitudinally administered PRONIA sample should investigate, whether there are differences in the course of the diseases related to CT experiences. Furthermore, suitable methods, such as structural equation models, should be used to highlight the exact relationship between CT and mental illness against the background of mediating variables and resilience factors.

## **Acknowledgements**

The authors would like to thank the entire PRONIA consortium for their excellent and valuable work.

### **# PRONIA Consortium**

The PRONIA consortium members listed here performed the screening, recruitment, rating, examination, and follow-up of the study participants and were involved in implementing the examination protocols of the study, setting up its information technological infrastructure, and organizing the flow and quality control of the data analyzed in this article between the local study sites and the central study database.

**Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Bavaria, Germany:** Mark Sen Dong, MSc, Anne Erkens, Eva Gussmann, MSc, Shalaila Haas, PhD, Alkomiet Hasan, MD, Claudius Hoff, MD, Ifrah Khanyaree, BSc, Aylin Melo, MSc, Susanna Muckenhuber-Sternbauer, MD, Janis Kohler, Ömer Faruk Öztürk, MD, Adrian Rangnick, BSc, Sebastian von Saldern, MD, Rachele Sanfelici, MSc, Moritz Spangemacher, Ana Tupac, MSc, Maria Fernanda Urquijo, MSc, Johanna Weiske, MSc, and Antonia Wosgien.

**University of Cologne, North Rhineland–Westphalia, Germany:** Karsten Blume, Tanja Pilgram, MSc, and Christiane Woopen, MD.

**Psychiatric University Hospital, University of Basel, Basel, Switzerland:** Christina Andreou, MD, PhD, Laura Egloff, PhD, Fabienne Harrisberger, PhD, Claudia Lenz, PhD, Letizia Leanza, MSc, Amatya Mackintosh, MSc, Renata Smieskova, PhD, Erich Studerus, PhD, Anna Walter, MD, and Sonja Widmayer, MSc.

**Institute for Mental Health, University of Birmingham, Birmingham, United Kingdom:** Chris Day, BSc, Sian Lowri Griffiths, PhD, Mariam Iqbal, BSc, Mirabel Pelton, MSc, Pavan Mallikarjun, MBBS, DPM, MRCPsych, PhD, and Ashleigh Lin, PhD.

**Department of Psychiatry, University of Turku, Turku, Finland:** Alexander Denissoff, MD, Anu Ellila, RN, Tiina From, MSc, Markus Heinimaa, MD, PhD, Tuula Ilonen, PhD, Paivi Jalo, RN, Heikki Laurikainen,

Haidl & Hedderich et al., 2020

MD, Maarit Lehtinen, RN, Antti Luutonen, BA, Akseli Makela, BA, Janina Paju, MSc, Henri Pesonen, PhD, Reetta-Liina Armio (Saila), MD, Elina Sormunen, MD, Anna Toivonen, MSc, and Otto Turtonen, MD.

**General Electric Global Research Inc, Munich, Germany:** Ana Beatriz Solana, PhD, Manuela Abraham, MBA, Nicolas Hehn, PhD, and Timo Schirmer, PhD.

**Workgroup of Paolo Brambilla, MD, PhD, University of Milan, Milan, Italy:** Department of Neuroscience and Mental Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy: Carlo Altamura, MD, Marika Belleri, PsychD, Francesca Bottinelli, PsychD, Adele Ferro, PsychD, PhD, and Marta Re, PhD. Programma 2000, Niguarda Hospital, Milan: Emiliano Monzani, MD, Mauro Percudani, MD, and Maurizio Sberna, MD. San Paolo Hospital, Milan: Armando D'Agostino, MD, and Lorenzo Del Fabro, MD. Villa San Benedetto Menni, Albese con Cassano: Giampaolo Perna, MD, Maria Nobile MD, PhD, and Alessandra Alciati, MD.

**Workgroup of Paolo Brambilla, MD, PhD, University of Udine, Udine, Italy:** Department of Medical Area, University of Udine: Matteo Balestrieri, MD, Carolina Bonivento, PsychD, PhD, Giuseppe Cabras, PhD, and Franco Fabbro, MD, PhD. IRCCS Scientific Institute "E. Medea", Polo FVG, Udine: Marco Garzitto, PsychD, PhD and Sara Piccin, PsychD, PhD. **Workgroup of Prof. Alessandro Bertolino, University of Bari Aldo Moro, Italy:** Prof. Giuseppe Blasi; Prof. Linda A. Antonucci, Prof. Giulio Pergola, Grazia Caforio, PhD, Leonardo Faio, PhD, Tiziana Quarto, PhD, Barbara Gelao, PhD, Raffaella Romano, PhD, Ileana Andriola, MD, Andrea Falsetti, MD, Marina Barone, MD, Roberta Passatiore, M.Sc., Marina Sangiuliano, MD.

**Department of Psychiatry and Psychotherapy, Westfaelische Wilhelms-University Muenster, North Rhineland–Westphalia, Germany:** Marian Surman, M.Sc., Olga Bienek, MD, Georg Romer, MD, Udo Dannlowski, MD, PhD.

Haidl & Hedderich et al., 2020

**Department of Psychiatry and Psychotherapy of the University Düsseldorf, North Rhineland–  
Westphalia, Germany:** Christian Schmidt-Kraepelin, MD, Susanne Neufang, PhD, Alexandra Korda,  
PhD, Henrik Rohner, MD

## References

- Albert, U., Tomassi, S., Maina, G., & Tosato, S. (2018). Prevalence of non-psychotic disorders in ultra-high risk individuals and transition to psychosis: A systematic review. *Psychiatry Research*, 270, 1-12. doi:10.1016/j.psychres.2018.09.028
- American Psychiatric Association. (2000). *Diagnostic and statistical manual of mental disorders: DSM-IV. (4th ed., text rev.)*. Washington, DC.
- Bentall, R. P., Wickham, S., Shevlin, M., & Varese, F. (2012). Do specific early-life adversities lead to specific symptoms of psychosis? A study from the 2007 the Adult Psychiatric Morbidity Survey. *Schizophrenia Bulletin*, 38(4), 734-740. doi:10.1093/schbul/sbs049
- Bernstein, D., & Fink, L. (1998). *Childhood Trauma Questionnaire: A retrospective self-report*. The Psychological Corporation: San Antonio.
- Bruni, A., Carbone, E. A., Pugliese, V., Aloï, M., Calabro, G., Cerminara, G., . . . De Fazio, P. (2018). Childhood adversities are different in Schizophrenic Spectrum Disorders, Bipolar Disorder and Major Depressive Disorder. *BMC Psychiatry*, 18(1), 391. doi:10.1186/s12888-018-1972-8
- Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group. (2017). *Drug misuse and dependence: UK guidelines on clinical management*. London.
- Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. (2015). Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD). *Annals of Internal Medicine*, 162(10), 735-736. doi:10.7326/L15-5093-2
- Colman, I., Kingsbury, M., Garad, Y., Zeng, Y., Naicker, K., Patten, S., . . . Thompson, A. H. (2016). Consistency in adult reporting of adverse childhood experiences. *Psychological Medicine*, 46(3), 543-549. doi:10.1017/S0033291715002032
- Fan, R. Chang, K; Hsieh, C; Wang, X; Lin, C. (2008). LIBLINEAR: A Library for Large Linear Classification. *Journal of Machine Learning Research*, 9(9), 1871-1874. doi: 10.1145/1390681.1442794

- Fang, X., Brown, D. S., Florence, C. S., & Mercy, J. A. (2012). The economic burden of child maltreatment in the United States and implications for prevention. *Child Abuse & Neglect*, 36(2), 156-165. doi:10.1016/j.chiabu.2011.10.006
- Gaser, C., & Dahnke, R. (2016). *CAT - A Computational Anatomy Toolbox for the Analysis of Structural MRI Data*. Retrieved from <http://www.neuro.uni-jena.de/hbm2016/GaserHBM2016.pdf>
- Golland, P., & Fischl, B. (2003). Permutation tests for classification: towards statistical significance in image-based studies. *Information Processing in Medical Imaging*, 18, 330-341. doi:10.1007/978-3-540-45087-0\_28
- Hautzinger, M., Bailer, M., Worall, H., & Keller, F. (1995). *Beck-Depressions-Inventar (BDI). Testhandbuch. 2. Auflage*. Hans Huber: Bern
- Hayasaka, Y., Purgato, M., Magni, L. R., Ogawa, Y., Takeshima, N., Cipriani, A., . . . Furukawa, T. A. (2015). Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. *Journal of Affective Disorders*, 180, 179-184. doi:10.1016/j.jad.2015.03.021
- Hudziak, J. (2009). Developmental psychopathology and wellness: Genetic and environmental influences. *American Psychiatric Publishing*, 267-287.
- Kambeitz, J., Kambeitz-Illankovic, L., Leucht, S., Wood, S., Davatzikos, C., Malchow, B., . . . Koutsouleris, N. (2015). Detecting neuroimaging biomarkers for schizophrenia: a meta-analysis of multivariate pattern recognition studies. *Neuropsychopharmacology*, 40(7), 1742-1751. doi:10.1038/npp.2015.22
- Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophrenia Bulletin*, 13(2), 261-276.
- Kessler, R. C., McLaughlin, K. A., Green, J. G., Gruber, M. J., Sampson, N. A., Zaslavsky, A. M., . . . Williams, D. R. (2010). Childhood adversities and adult psychopathology in the WHO World Mental Health Surveys. *British Journal of Psychiatry*, 197(5), 378-385. doi:10.1192/bjp.bp.110.080499



Koutsouleris, N., Kambeitz-Ilankovic, L., Ruhrmann, S., Rosen, M., Ruef, A., Dwyer, D. B., . . .

Consortium, P. (2018). Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression: A Multimodal, Multisite Machine Learning Analysis. *JAMA Psychiatry*, 75(11), 1156-1172. doi:10.1001/jamapsychiatry.2018.2165

Lee, D., Yu, E. S., & Kim, N. H. (2020). Resilience as a mediator in the relationship between posttraumatic stress and posttraumatic growth among adult accident or crime victims: the moderated mediating effect of childhood trauma. *European Journal of Psychotraumatology*, 11(1), 1704563. doi:10.1080/20008198.2019.1704563

Leucht, S., Samara, M., Heres, S., & Davis, J. M. (2016). Dose Equivalents for Antipsychotic Drugs: The DDD Method. *Schizophrenia Bulletin*, 42 Suppl 1, S90-94. doi:10.1093/schbul/sbv167

Lindert, J., von Ehrenstein, O. S., Grashow, R., Gal, G., Braehler, E., & Weisskopf, M. G. (2014). Sexual and physical abuse in childhood is associated with depression and anxiety over the life course: systematic review and meta-analysis. *International Journal of Public Health*, 59(2), 359-372. doi:10.1007/s00038-013-0519-5

Marshall, M., Shannon, C., Meenagh, C., Mc Corry, N., & Mulholland, C. (2018). The association between childhood trauma, parental bonding and depressive symptoms and interpersonal functioning in depression and bipolar disorder. *Irish Journal of Psychological Medicine*, 35(1), 23-32. doi:10.1017/ipm.2016.43

McGlashan, T., Walsh, B., & Woods, S. (2010). *The psychosis-risk syndrome: handbook for diagnosis and follow-up*. Oxford University Press: Oxford.

Mikton, C., & Butchart, A. (2009). Child maltreatment prevention: a systematic review of reviews. *Bulletin of the World Health Organization*, 87(5), 353-361. doi:10.2471/blt.08.057075

Nelson, J., Klumparendt, A., Doeblen, P., & Ehring, T. (2017). Childhood maltreatment and characteristics of adult depression: meta-analysis. *British Journal of Psychiatry*, 210(2), 96-104. doi:10.1192/bjp.bp.115.180752

- Palmier-Claus, J. E., Berry, K., Bucci, S., Mansell, W., & Varese, F. (2016). Relationship between childhood adversity and bipolar affective disorder: systematic review and meta-analysis. *British Journal of Psychiatry*, 209(6), 454-459. doi:10.1192/bjp.bp.115.179655
- Phillips, L. J., Yung, A. R., & McGorry, P. D. (2000). Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. *Australian and New Zealand Journal of Psychiatry*, 34 Suppl, S164-169. doi:10.1080/000486700239
- Popovic, D., Ruef, A., Dwyer, D., Antonucci, L., Eder, J., Sanfelici, R., . . . Koutsouleris, N. (2020). Traces of trauma – a multivariate pattern analysis of childhood trauma, brain structure and clinical phenotypes. *Biological Psychiatry*, 88(11), 829-842. doi:10.1016/j.biopsych.2020.05.020.
- Rubino, I. A., Nanni, R. C., Pozzi, D. M., & Siracusano, A. (2009). Early adverse experiences in schizophrenia and unipolar depression. *Journal of Nervous and Mental Disease*, 197(1), 65-68. doi:10.1097/NMD.0b013e3181925342
- Sahin, S., Yuksel, C., Guler, J., Karadayi, G., Akturan, E., Gode, E., . . . Ucock, A. (2013). The history of childhood trauma among individuals with ultra high risk for psychosis is as common as among patients with first-episode schizophrenia. *Early Intervention in Psychiatry*, 7(4), 414-420. doi:10.1111/eip.12022
- Salokangas, R. K. R., From, T., Luutonen, S., & Hietala, J. (2018). Adverse childhood experiences leads to perceived negative attitude of others and the effect of adverse childhood experiences on depression in adulthood is mediated via negative attitude of others. *European Psychiatry*, 54, 27-34. doi:10.1016/j.eurpsy.2018.06.011
- Salokangas, R. K. R., From, T., Luutonen, S., Salokangas, H. R. W., & Hietala, J. (2018). Effect of childhood adversities on alcohol problems is mainly mediated by depression. *The American Journal on Addictions*. doi:10.1111/ajad.12734
- Salokangas, R. K. R., Hietala, J., Armio, R. L., Laurikainen, H., From, T., Borgwardt, S., . . . Koutsouleris, N. (2021). Effect of childhood physical abuse on social anxiety is mediated via reduced frontal

- lobe and amygdala-hippocampus complex volume in adult clinical high-risk subjects. *Schizophrenia Research*, 227, 101-109. doi:10.1016/j.schres.2020.05.041
- Salokangas, R. K. R., Patterson, P., Hietala, J., Heinimaa, M., From, T., Ilonen, T., . . . Ruhrmann, S. (2019). Childhood adversity predicts persistence of suicidal thoughts differently in females and males at clinical high-risk patients of psychosis. Results of the EPOS project. *Early Intervention Psychiatry*, 13(4), 935-942. doi:10.1111/eip.12714
- Scher, C. D., Forde, D. R., McQuaid, J. R., & Stein, M. B. (2004). Prevalence and demographic correlates of childhood maltreatment in an adult community sample. *Child Abuse & Neglect*, 28(2), 167-180. doi:10.1016/j.chiabu.2003.09.012
- Schultze-Lutter, F., Addington, J., Ruhrmann, S., & Klosterkötter, J. (2007). *Schizophrenia Proneness Instrument, Adult Version (SPI-A)*. Giovanni Fioriti Editore: Rom.
- Scott, K. M., McLaughlin, K. A., Smith, D. A., & Ellis, P. M. (2012). Childhood maltreatment and DSM-IV adult mental disorders: comparison of prospective and retrospective findings. *British Journal of Psychiatry*, 200(6), 469-475. doi:10.1192/bjp.bp.111.103267
- Smith, S. M., & Nichols, T. E. (2009). Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. *Neuroimage*, 44(1), 83-98. doi:10.1016/j.neuroimage.2008.03.061
- Steyerberg, E. W., & Harrell, F. E., Jr. (2016). Prediction models need appropriate internal, internal-external, and external validation. *Journal of Clinical Epidemiology*, 69, 245-247. doi:10.1016/j.jclinepi.2015.04.005
- Trauelson, A. M., Bendall, S., Jansen, J. E., Nielsen, H. G., Pedersen, M. B., Trier, C. H., . . . Simonsen, E. (2015). Childhood adversity specificity and dose-response effect in non-affective first-episode psychosis. *Schizophrenia Research*, 165(1), 52-59. doi:10.1016/j.schres.2015.03.014
- Upthegrove, R., Chard, C., Jones, L., Gordon-Smith, K., Forty, L., Jones, I., & Craddock, N. (2015). Adverse childhood events and psychosis in bipolar affective disorder. *British Journal of Psychiatry*, 206(3), 191-197. doi:10.1192/bjp.bp.114.152611

Varese, F., Smeets, F., Drukker, M., Lieveise, R., Lataster, T., Viechtbauer, W., . . . Bentall, R. P. (2012).

Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. *Schizophrenia Bulletin*, 38(4), 661-671.

doi:10.1093/schbul/sbs050

## **Tables**

**Table 1:** Sociodemographic data and general psychopathology. Comparison between healthy controls and patients

**Table 2:** Multivariate analyses

**Table 3:** CTQ-class probabilities associations with psychopathology

## **Figure legends**

**Figure 1:** Predictive pattern of the single CTQ items and related subdomains in the different diagnostic groups

## **Supplement**

### **Supplement Tables**

**Supplement Table 1:** Study inclusion / exclusion criteria of the study

**Supplement Table 2:** MR scanner systems and structural MRI sequence parameters used at the respective PRONIA sites

**Supplement Table 3:** Comparison of CTQ subscales across groups

**Supplemental Table 4:** Mean values of medication dose equivalents taken cumulatively over lifetime (mg/d)

**Supplemental Table 5:** CTQ-class probabilities associations with age

**Supplemental Table 6:** CTQ-class probabilities associations with medication dose equivalents taken cumulatively over lifetime

### **Supplement Figures**

**Supplement Figure 1:** Study design

**Supplement Figure 2:** Consort Chart

### **Supplement Methods**

**Supplement Method:** Nested leave-site-out cross-validation


Haidl & Hedderich et al., 2020

**Conflicts of interest**

None

Figure 1

[Click here to access/download;Figure\(s\);CTQ\\_Figure\\_1\\_BlackandWhite.tiff](#)





**Table 3:** CTQ-class probabilities associations with psychopathology

	$r_s$	p
<b>All groups</b>		
GAF Symptoms	.388	<.001**
GAF Disability/Impairment	.412	<.001**
<b>CHR</b>		
SIPS-P	-.103	.259
SIPS-N	-.116	.206
SIPS-D	-.014	.882
SIPS-G	.026	.777
BDI-II	-.175	.028*
PANSS Total	-.191	.038*
PANSS Positive	-.127	.168
PANSS Negative	-.196	.033*
PANSS General	-.126	.174
<b>ROD</b>		
SIPS Positive	.018	.839
SIPS Negative	.010	.908
SIPS Disorganizing	-.124	.166
SIPS General	-.106	.236
BDI-II	-.278	.001**
PANSS Total	-.017	.854
PANSS Positive	-.120	.182
PANSS Negative	-.025	.782
PANSS General	-.008	.928
<b>ROP</b>		
SIPS Positive	-.042	.638
SIPS Negative	-.230	.10
SIPS Disorganizing	-.139	.125
SIPS General	-.050	.581
BDI-II	-.246	.003**
PANSS-T	-.107	.117
PANSS-P	-.097	.141
PANSS-N	-.115	.100
PANSS-G	-.083	.177

CHR, Clinical High-Risk state; ROD, Recent Onset Depression; ROP, Recent Onset Psychosis; PANSS, Positive and Negative Syndrome Scale; BDI-II, Beck Depression Inventory II; SIPS, Structured Interview for Prodromal Symptoms; GAF, Global Assessment of Functioning;  $r_s$ , Spearmans Correlation Coefficient

\*Significant at the level of 0.05

\*\*Significant at the level of <0.01

**Table 2:** Multivariate analyses

Classifier	TP	TN	FP	FN	Sens	Spec	BAC	PPV	NPV	PSI	AUC	P <sup>a</sup>
<i>Leave-site-out performance</i>												
<b>HC vs PAT (L2LR)</b>	186	266	112	72	72.1	70.4	<b>71.2</b>	62.4	78.7	41.1	0.77	<.001
<b>HC vs PAT (GLM)</b>	173	260	121	89	66	68.2	<b>67.1</b>	58.8	74.5	33.3	0.74	<.001
<b>ROD vs ROP</b>	69	55	65	50	58.0	45.3	<b>51.9</b>	51.5	52.4	3.9	0.49	0.358
<b>CHR vs ROP</b>	51	62	58	69	42.5	51.7	<b>47.1</b>	46.8	47.3	-5.9	0.48	0.866
<b>CHR vs ROD</b>	43	67	52	77	35.8	56.3	<b>46.1</b>	45.3	46.5	-8.2	0.43	0.923
<b>HC vs ROD</b>	198	76	53	64	75.6	58.9	<b>67.2</b>	78.9	54.3	33.2	0.69	<.001
<b>HC vs CHR</b>	189	84	33	72	72.4	71.8	<b>72.1</b>	85.1	53.8	39.0	0.72	<.001
<b>HC vs ROP</b>	195	86	42	67	74.4	67.2	<b>70.8</b>	82.3	56.2	38.5	0.75	<.001
<i>Leave-group-out performance</i>												
<b>HC vs CHR OOCV ROP</b>	249	51	78	13	95	39.5	<b>67.3</b>	76.1	79.7	55.8	0.79	<.001
<b>HC vs CHR OOCV ROD</b>	249	38	92	13	95	29.2	<b>62.1</b>	73.0	74.5	47.5	0.74	<.001
<b>HC vs ROD OOCV ROP</b>	249	51	78	13	95	39.5	<b>67.3</b>	76.1	79.7	55.8	0.76	<.001
<b>HC vs ROD OOCV CHR</b>	249	48	74	13	95	39.3	<b>67.2</b>	77.1	78.7	55.8	0.77	<.001
<b>HC vs ROP OOCV CHR</b>	248	49	73	14	94.7	40.2	<b>67.4</b>	77.3	77.8	55.0	0.79	<.001
<b>HC vs ROP OOCV ROD</b>	248	45	85	14	94.7	34.6	<b>64.6</b>	74.5	76.3	50.7	0.71	<.001

All analyses were single item based, Abbreviations: TP = True positive, TN = True negative, FP = False positive, FN = False negative, Sens = Sensitivity, Spec = Specificity, BAC = Balanced Accuracy, PPV = Positive Predictive Value, NPV = Negative Predictive Value, PSI = Prognostic Summary Index, AUC = Area-under-the Curve, HC = Healthy controls, PAT = patients including ROP, ROD and CHR; ROD = Recent Onset Depression, ROP = Recent Onset Psychosis, CHR = Clinically High-Risk, OOCV = Out-Of-Sample Cross-Validation

**Table 1: Sociodemographic data and general psychopathology. Comparison between healthy controls and patients**

	HC	PAT	U / $\chi^2$ <sup>a</sup>	p <sup>a</sup>	CHR	ROD	ROP
<b>n</b> total (%)	262 (40.7%)	381 (59.3)	n.a.	n.a.	122 (19.0%)	130 (20.2%)	129 (20.1%)
<b>Age (y),</b> M (SD)	27.75 (6.41)	27.64 (5.68)	49854	0.932	26.26 (4.9)	28.54 (6.14)	28.02 (5.68)
<b>Sex (♀)</b> F (%)	164 (62.6%)	204 (53.5)	16.23	<.001	58 (47.5%)	70 (53.8%)	49 (38%)
<b>Psychopathology [Mean (SD)]</b>							
<b>BDI-II</b>	3.76 (5.27)	24.12 (13.04)	6273.5	<.001	24.89 (12.16)	26.71 (13.91)	20.79 (12.30)
<b>CTQ</b>	30.88 (6.4)	40.38 (12.64)	20806.5	<.001	41.28 (12.73)	39.33 (13.66)	40.57 (11.42)
<b>PANSS Total</b>	n.a.	56.32 (18.90)	n.a.	n.a.	50.74 (13.11)	47.80 (11.33)	70.11 (21.70)
<b>PANSS Negative</b>	n.a.	13.83 (6.39)	n.a.	n.a.	12.54 (5.83)	12.60 (5.00)	16.27 (7.38)
<b>PANSS Positive</b>	n.a.	11.97 (6.05)	n.a.	n.a.	10.27 (2.95)	7.71 (1.39)	17.84 (6.52)
<b>PANSS General</b>	n.a.	30.49 (9.39)	n.a.	n.a.	27.83 (6.88)	27.48 (6.97)	35.99 (11.07)
<b>Childhood Trauma</b>							
<b>Emotional Abuse</b>	6.56 (2.42)	9.64 (4.37)	24784.0	<.001	10.16 (4.43)	9.2 (4.36)	9.62 (4.29)
<b>Physical Abuse</b>	5.39 (1.0)	6.52 (3.08)	38805.5	<.001	6.56 (3.11)	6.45 (3.21)	6.56 (3.0)
<b>Sexual Abuse</b>	5.2 (1.1)	6.04 (2.95)	39828.5	<.001	5.97 (2.77)	5.88 (2.84)	6.28 (3.22)
<b>Emotional Neglect</b>	7.93 (3.14)	11.47 (4.58)	25248.5	<.001	11.78 (4.45)	11.25 (4.88)	11.4 (4.42)
<b>Physical Neglect</b>	5.87 (1.51)	7.41 (2.73)	29420.0	<.001	7.35 (2.6)	7.08 (2.81)	7.79 (2.76)
<b>Distribution across sites (total/%)</b>							
<b>Munich</b>	59 (22.5)	125 (32.8)	n.a.	n.a.	40 (32.8)	44 (33.8)	41 (31.8)
<b>Basel</b>	44 (16.8)	51 (13.4)	n.a.	n.a.	18 (14.8)	17 (13.1)	16 (12.4)
<b>Cologne</b>	56 (21.4)	69 (18.1)	n.a.	n.a.	18 (14.8)	25 (19.2)	26 (20.2)
<b>Birmingham</b>	42 (16.0)	34 (8.9)	n.a.	n.a.	13 (10.7)	12 (9.2)	9 (7.0)
<b>Turku</b>	19 (7.3)	45 (11.8)	n.a.	n.a.	14 (11.5)	11 (8.5)	20 (15.5)
<b>Udine</b>	31 (11.8)	31 (8.1)	n.a.	n.a.	12 (9.8)	14 (10.8)	5 (3.9)
<b>Milan</b>	11 (4.2)	26 (6.8)	n.a.	n.a.	7 (5.7)	7 (5.4)	12 (9.3)

Statistical comparisons: sex with  $\chi^2$  statistics ; age, BDI-II and CTQ with Mann-Whitney-U Test. Abbreviations: U, Mann-Whitney-U Test;  $\chi^2$ , chi-squared test, M, mean; SD, standard deviation; PAT= patients including ROP, ROD and CHR; HC, Healthy Controls; CHR, Clinical High-Risk state; ROD, Recent Onset Depression; ROP, Recent Onset Psychosis; CTQ, childhood trauma questionnaire, PANSS, Positive and Negative Syndrom Scale; BDI-II, Beck Depression Inventory II,<sup>a</sup> comparison only between PAT and HC

**Supplement Table 1:** Study inclusion / exclusion criteria of the study.

Group Inclusion Criteria	Group Exclusion Criteria	General Inclusion / Exclusion / Drop-out
Clinical High-Risk Group (CHR)		<b>Inclusion Criteria:</b> <ol style="list-style-type: none"><li>Age 15 to 40 years</li><li>Language skills sufficient for participation</li><li>Able to provide to consent / assent</li></ol> <b>Exclusion Criteria:</b> <ol style="list-style-type: none"><li>IQ below 70</li><li>Hearing is not sufficient for neuro-cognitive testing</li><li>Current or past head trauma with loss of consciousness (&gt; 5 min)</li><li>Current or past known neurological disorder of the brain</li><li>Current or past known somatic disorder potentially affecting the structure or functioning of the brain</li><li>Current or past alcohol dependence</li><li>Current poly-substance dependence or within the past six months (Note: any combination with E.6. led to exclusion)</li><li>Any contra-indication for MRI</li></ol> <b>Exclusion criteria for healthy controls:</b> <ol style="list-style-type: none"><li>Any current or past DSM-IV axis disorder</li><li>A positive familial history (1st degree relatives) for affective or non-affective psychoses or major affective disorders; and</li><li>An intake of psychotropic medications or drugs more than 5 times/year and in the month before study inclusion.</li></ol> <b>Drop-out criteria:</b> <ol style="list-style-type: none"><li>No follow-up examination after the 6-months follow-up examination (IV6)</li><li>Withdrawn consent / assent</li></ol>
<b>Psychosis-risk syndrome defined:</b> <p><b>EITHER</b> by <i>Attenuated Positive Symptoms (APS)</i>, as measured by the SIPS (requires 1 of 5 attenuated psychotic symptoms: unusual thought content/ delusional ideas, suspiciousness/persecutory ideas, grandiosity, perceptual abnormalities/hallucinations, and disorganized communication) with a moderate to severe, but not psychotic, severity (SIPS score 3-5) that (1) began with-in the past year or was rated one or more scale points higher compared to 12 month ago, <b>AND</b> (2) occurred at an average frequency of at least once per week for at least several minutes per event in the past month</p> <p><b>OR:</b> by <i>Brief Intermittent Psychotic Symptoms (BLIPS)</i>, as measured by the SIPS (as defined by one of the symptoms listed above (1) reaching a psychotic level of intensity in each of the past 3 months for at least several minutes per day, <b>OR</b> (2) reaching a psychotic level of intensity in the past month, occurring at an average frequency of at least once per week for at least several minutes per event in the past month, or occurring at least for a cumulative period of more than one hour within the past month, <b>AND</b> (1+2) remitting spontaneously within one week (i.e. without antipsychotic medication)</p> <p><b>OR:</b> by a <i>Genetic Risk and Functional Decline Psychosis-Risk Syndrome (GRFD)</i> defined by a current 30% or greater reduction in the functional disability score of the split version of the Global Assessment of Functioning Scale (GAF-F) compared with the highest lifetime level of functioning, <b>AND</b> (having a first-degree relative with a history of any psychotic disorder, <b>OR</b> having a DSM-IV-TR schizotypal personality disorder).</p> <p><b>OR:</b> by a <i>Cognitive Disturbance Syndrome (COGDIS)</i> as measured by the SPI-A (requires at least 2 of 9 cognitive basic symptoms with at least weekly occurrence (score ≥3) during the last 3 months)</p>	<ol style="list-style-type: none"><li>Any intake of antipsychotic medication for more than 30 cumulative days at or above the minimum dosage threshold defined by the DGPPN S3 Guidelines for the treatment of first-episode psychosis<sup>1</sup></li><li>Any intake of antipsychotic drugs within the past 3 months before psychopathological baseline assessments at or above the minimum dosage threshold.</li><li>Occurrence of the CHR syndrome is better explained by other DSM-IV disorder</li></ol>	
Recent-Onset Depression (ROD)		
<b>Recent-onset Depression as defined by DSM-IV-TR + ALL of the following criteria:</b> <ol style="list-style-type: none"><li>First life-time depressive episode,</li><li>Duration of current depressive episode no longer than 24 months,</li><li>Diagnostic criteria fulfilled within past three months</li></ol>	<ol style="list-style-type: none"><li>Occurrence of the major depressive episode is better explained by other DSM-IV disorder</li><li>See CHR exclusion criteria</li></ol>	
Recent-Onset Psychosis (ROP)		
<b>Recent-onset Psychosis as defined by DSM-IV-TR (affective and non-affective) + ALL of the following criteria:</b> <ol style="list-style-type: none"><li>First life-time psychotic episode,</li><li>Duration of current psychotic episode no longer than 24 months,</li><li>Diagnostic criteria fulfilled within past three months</li></ol>	<ol style="list-style-type: none"><li>Occurrence of the psychotic episode is better explained by other DSM-IV disorder</li><li>Antipsychotic medication for more than 90 days at or above the minimum dosage defined by the DGPPN S3 Guidelines for the treatment of first-episode psychosis<sup>1</sup></li></ol>	

<sup>1</sup> Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde. DGPPN S3 Treatment Guideline Schizophrenia / Psychotic Disorders. AWMF 2006.

**Supplement Table 2:** MR scanner systems and structural MRI sequence parameters used at the respective PRONIA sites

PRONIA Site	Model	Field strength [3T]	Coil channels	Flip angle [deg]	TR [ms]	TE [ms]	Voxel size [mm]	FOV	Slice number
Munich	Philips Ingenia	3	32	8	9.5	5.5	0.97x0.9 7x1.0	250 x 250	190
Milan Niguarda	Philips Achieva Intera	1.5	8	12	Shortest (8.1)	Shortest (3.7)	0.93x0.9 3x1.0	240 x 240	170
Basel	Siemens Verio	3	12	8	2000	3.4	1.0x1.0x 1.0	256 x 256	176
Cologne	Philips Achieva	3	8	8	9.5	5.5	0.97x0.9 7x1.0	250 x 250	190
Birmingham	Philips Achieva	3	32	8	8.4	3.8	1.0x1.0x 1.0	288 x 288	175
Turku	Philips Ingenuity	3	32	7	8.1	3.7	1.0x1.0x 1.0	256 x 256	176
Udine	Philips Achieva	3	8	12	Shortest (8.1)	Shortest (3.7)	0.93x0.9 3x1.0	240 x 240	170

Supplement Table 3: Comparison of CTQ subscales across groups

CTQ Subscale			Average difference	Standard error	p
Emotional Abuse					
HC	CHR	CHR	-3.60*	0.41	<.001
		ROD	-2.6*	0.4	<.001
		ROP	-3.06*	0.4	<.001
CHR	HC	HC	3.60*	0.41	<.001
		ROD	0.99	0.47	0.15
		ROP	0.53	0.47	0.67
ROD	HC	HC	2.6*	0.4	<.001
		CHR	-0.99	0.47	0.15
		ROP	-0.46	0.46	0.76
ROP	HC	HC	3.06*	0.4	<.001
		CHR	-0.53	0.47	0.67
		ROD	0.46	0.46	0.76
Physical Abuse					
HC	CHR	CHR	-1.17*	0.27	<.001
		ROD	-1.05*	0.27	<.001
		ROP	-1.17*	0.27	<.001
CHR	HC	HC	1.17*	0.27	<.001
		ROD	0.11	0.31	0.98
		ROP	-0.004	0.31	1.00
ROD	HC	HC	1.05*	0.27	<.001
		CHR	-0.11	0.31	0.98
		ROP	-0.12	0.31	0.98
ROP	HC	HC	1.17*	0.27	<.001
		CHR	0.004	0.31	1.00
		ROD	0.12	0.31	0.98
Sexual Abuse					
HC	CHR	CHR	-0.77*	0.26	0.02
		ROD	-0.69*	0.26	0.04
		ROP	-1.09*	0.26	<.001
CHR	HC	HC	0.77*	0.26	0.02
		ROD	0.08	0.3	0.99
		ROP	-0.32	0.3	0.72
ROD	HC	HC	0.69*	0.26	0.04
		CHR	-0.08	0.3	0.99
		ROP	-0.4	0.3	0.53
ROP	HC	HC	1.09*	0.26	<.001
		CHR	0.32	0.3	0.72
		ROD	0.4	0.3	0.53
Emotional Neglect					
HC	CHR	CHR	-3.85*	0.45	<.001
		ROD	-3.31*	0.44	<.001
		ROP	-3.47*	0.44	<.001
CHR	HC	HC	3.85*	0.45	<.001
		ROD	0.54	0.52	0.73
		ROP	0.39	0.52	0.88
ROD	HC	HC	3.31*	0.44	<.001
		CHR	-0.54	0.52	0.73
		ROP	-0.15	0.51	0.99
ROP	HC	HC	3.47*	0.44	<.001
		CHR	-0.38	0.52	0.88
		ROD	0.15	0.51	0.99

**Physical Neglect**

HC	CHR	-1.48*	0.26	<.001
	ROD	-1.21*	0.25	<.001
	ROP	-1.92*	0.25	<.001
CHR	HC	1.48*	0.26	<.001
	ROD	0.27	0.29	0.79
	ROP	-0.43	0.29	0.45
ROD	HC	1.21*	0.25	<.001
	CHR	-0.27	0.29	0.79
	ROP	-0.71	0.29	0.07
ROP	HC	1.92*	0.25	<.001
	CHR	0.43	0.29	0.45
	ROD	0.71	0.29	0.07

Abbreviations: HC, Healthy Controls; CHR, Clinical High-Risk state; ROD, Recent Onset Depression; ROP, Recent Onset Psychosis; CTQ, childhood trauma questionnaire

\*Significant at the level of 0.05

**Supplement Table 4:** *Mean values of medication dose equivalents taken cumulatively over lifetime (mg/d)*

		CHLORPROMAZINE	OLANZAPINE	SSRI	BENZODIAZEPINE
ALL GROUPS	M	1919.98	68.16	1617.69	121.52
	N	623	623	623	623
	SD	8906.37	307.86	6417.95	651.69
HC	M	0	0	0	16.10
	N	250	250	250	250
	SD	0	0	0	232.24
ROD	M	504.47	19.05	2630.83	142.59
	N	129	129	129	129
	SD	2033.96	78.42	6682.12	556.91
CHR	M	1025.06	42.04	3864.95	123.49
	N	119	119	119	119
	SD	5463.24	235.20	8371.53	649.41
ROP	M	8072.71	280.02	1668.10	308.74
	N	125	125	125	125
	SD	17798.21	598.88	9090.62	1114.60

M, mean; SD, standard deviation; HC, Healthy Controls; CHR, Clinical High-Risk state; ROD, Recent Onset Depression; ROP, Recent Onset Psychosis; Chlorpromazine; Chlorpromazine equivalent, Olanzapine; Olanzapine equivalent, SSRI; SSRI equivalent, Benzodiazepine; Benzodiazepine (Diazepam) equivalent





**Supplement Table S5:** *CTQ-class probabilities associations with age*

	<b>r<sub>s</sub></b>	<b>p</b>
All groups	-.018	.648
HC	.029	.640
CHR	-.157	0.83
ROD	-0.034	.703
ROP	-.002	.986

CHR, Clinical High-Risk state; ROD, Recent Onset Depression; ROP, Recent Onset Psychosis; *r<sub>s</sub>*, Spearmans Correlation Coefficient

**Supplement Table S6:** *CTQ-class probabilities associations with medication dose equivalents taken cumulatively over lifetime*

	$r_s$	p
<b>All groups</b>		
Chlorpromazine	-.213	<0.001
Olanzapine	-.213	<0.001
SSRI	-.193	<0.001
Benzodiazepine	-.128	0.001
<b>HC</b>		
Chlorpromazine	n.a.	n.a.
Olanzapine	n.a.	n.a.
SSRI	n.a.	n.a.
Benzodiazepine	.141	0.013
<b>CHR</b>		
Chlorpromazine	-0.045	0.314
Olanzapine	-0.043	0.319
SSRI	0.015	0.437
Benzodiazepine	-0.038	0.341
<b>ROD</b>		
Chlorpromazine	0.058	0.255
Olanzapine	0.059	0.254
SSRI	0.047	0.298
Benzodiazepine	0.058	0.258
<b>ROP</b>		
Chlorpromazine	-0.002	.491
Olanzapine	-0.006	.472
SSRI	0.004	.481
Benzodiazepine	0.029	.374

CHR, Clinical High-Risk state; ROD, Recent Onset Depression; ROP, Recent Onset Psychosis;  $r_s$ , Spearmans Correlation Coefficient, Chlorpromazine; Chlorpromazine equivalent, Olanzapine; Olanzapine equivalent, SSRI; SSRI equivalent, Benzodiazepine; Benzodiazepine (Diazepam) equivalent

### **Supplement Method:** Nested leave-site-out cross-validation

On the outer LOSOCV cycle ( $CV_2$ ), the entire population was split into the seven sites. Each of these samples was iteratively held back as validation data, while the six remaining samples entered the inner CV loop. Hence, this outer CV loop provided a robust and unbiased estimate of the classification generalizability because all validation samples were strictly separated from the entire training process taking place at the inner loop ( $CV_1$ ). A 10-fold CV with 10 repetitions was used at this inner loop, to generate classifier ensembles and the outer loop was repeated 5 times to further increase robustness of the generalizability assessments.

Specifically, in each of these training partitions, the CTQ-items were scaled feature-wise to a range of [0, 1]. Because of missing values (3.8% missing), we used a nearest neighbor-based imputation approach employing the Hamming distance<sup>1</sup> suitable for ordinal data. Then, the scaled and imputed data matrix was z-normalized to the training sample's means and standard deviations before it entered sequential backward elimination (SBE) algorithm that employed  $L_2$ -regularized logistic regression (L2-LR)<sup>2</sup> as provided by the LIBLINEAR library<sup>2</sup> in NeuroMiner. The SBE algorithm iteratively removed CTQ items from the item pool that decreased average model performance in the  $CV_1$  training and  $CV_1$  test data. An early stopping criterion at 50% of the variables remaining in the pool was introduced to avoid an overfitting of the algorithm. To further increase feature extraction stability, a probabilistic feature extraction step identified those CTQ items that were selected by at least 90% of the  $CV_1$  models in the given  $CV_2$  training partition. CTQ items not meeting this criterion were pruned from the feature pool and models were retrained with the remaining features using the entire  $CV_1$  data partition.

To predict the group membership of unknown individuals in the  $CV_2$  validation partitions, the scaling, imputation and z-normalization models developed in the training sample were first applied to these cases, followed by the computation of class membership probabilities by means of the trained L2-LR models. The class membership predictions produced by these  $CV_1$  models for the unseen validation cases in each held-back site were bagged into an classification ensemble by means of averaging and majority voting<sup>3</sup>. Thus, an average CTQ-based class probability / decision score (DS) was calculated for each individual, predicting its out-of-training (OOT) group membership.

### **References**

1. Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, Tibshirani R, Botstein D, Altman RB. Missing value estimation methods for DNA microarrays. *Bioinformatics* Jun 2001;17(6):520-525.
2. Fan RC, K; Hsieh, C; Wang, X; Lin, C; . LIBLINEAR: A Library for Large Linear Classification. 2008.

3. Polikar R, Topalis A, Green D, Kounios J, Clark CM. Comparative multiresolution wavelet analysis of ERP spectral bands using an ensemble of classifiers approach for early diagnosis of Alzheimer's disease. *Comput Biol Med* Apr 2007;37(4):542-558.

